HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor OTC opinions

This article was originally published in The Tan Sheet

Executive Summary

American Pharmacists Association supports a "strong role" for pharmacists if an Rx-to-OTC switch of lovastatin 20 mg were to be approved, former APhA President Janet Engle says Jan. 14. An APhA task force developed the "pharmacy care OTC" category for drugs to treat chronic, asymptomatic conditions last fall (1"The Tan Sheet" Nov. 8, 2004, p. 10). J&J/Merck says OTC Mevacor should be sold only in retail outlets with a pharmacy. FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees voted 20-3 against the switch...

You may also be interested in...



“Pharmacy Care” OTC Category Considered By APhA Task Force

A new category of "pharmacy care" drugs could broaden access to certain over-the-counter drugs, according to the American Pharmacists Association

QUOTED. 30 September 2020. Andrew Newlands.

ANGLE plc’s Parsortix system could become the first FDA-cleared device for harvesting intact cancer cells from a blood sample. See what CEO Andrew Newlands said about its potential benefits.

One Goal, Four Paths: Comparing COVID-19 Vaccine Pivotal Trial Protocols

Phase III protocols for COVID-19 vaccine candidates from Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson are similar – but definitely not the same.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel